TherapeuticsMD, Inc.
TherapeuticsMD, Inc. TXMD Peers
See (TXMD) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TXMD | $1.09 | +0.93% | 12.6M | -5.74 | -$0.19 | N/A |
| ZTS | $157.18 | +1.37% | 70B | 28.22 | $5.57 | +1.19% |
| HLN | $10.42 | -0.33% | 46.9B | 24.80 | $0.42 | +1.61% |
| TAK | $14.76 | -0.94% | 46.5B | 64.17 | $0.23 | +4.00% |
| TEVA | $16.97 | -0.56% | 19.5B | -14.75 | -$1.15 | N/A |
| RGC | $38.01 | -40.00% | 18.8B | -3801.00 | -$0.01 | N/A |
| ITCI | $131.87 | N/A | 14B | -180.64 | -$0.73 | N/A |
| RDY | $15.23 | +0.23% | 12.7B | 19.28 | $0.79 | +0.63% |
| NBIX | $126.55 | -0.60% | 12.5B | 42.90 | $2.95 | N/A |
| CTLT | $63.48 | N/A | 11.5B | -27.84 | -$2.28 | N/A |
Stock Comparison
TXMD vs ZTS Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, ZTS has a market cap of 70B. Regarding current trading prices, TXMD is priced at $1.09, while ZTS trades at $157.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas ZTS's P/E ratio is 28.22. In terms of profitability, TXMD's ROE is -0.08%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, TXMD is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs HLN Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, HLN has a market cap of 46.9B. Regarding current trading prices, TXMD is priced at $1.09, while HLN trades at $10.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas HLN's P/E ratio is 24.80. In terms of profitability, TXMD's ROE is -0.08%, compared to HLN's ROE of +0.09%. Regarding short-term risk, TXMD is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs TAK Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, TAK has a market cap of 46.5B. Regarding current trading prices, TXMD is priced at $1.09, while TAK trades at $14.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas TAK's P/E ratio is 64.17. In terms of profitability, TXMD's ROE is -0.08%, compared to TAK's ROE of +0.04%. Regarding short-term risk, TXMD is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs TEVA Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, TEVA has a market cap of 19.5B. Regarding current trading prices, TXMD is priced at $1.09, while TEVA trades at $16.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas TEVA's P/E ratio is -14.75. In terms of profitability, TXMD's ROE is -0.08%, compared to TEVA's ROE of -0.21%. Regarding short-term risk, TXMD is more volatile compared to TEVA. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs RGC Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, RGC has a market cap of 18.8B. Regarding current trading prices, TXMD is priced at $1.09, while RGC trades at $38.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas RGC's P/E ratio is -3801.00. In terms of profitability, TXMD's ROE is -0.08%, compared to RGC's ROE of -0.25%. Regarding short-term risk, TXMD is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs ITCI Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, TXMD is priced at $1.09, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas ITCI's P/E ratio is -180.64. In terms of profitability, TXMD's ROE is -0.08%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, TXMD is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs RDY Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, RDY has a market cap of 12.7B. Regarding current trading prices, TXMD is priced at $1.09, while RDY trades at $15.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas RDY's P/E ratio is 19.28. In terms of profitability, TXMD's ROE is -0.08%, compared to RDY's ROE of +0.18%. Regarding short-term risk, TXMD is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs NBIX Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, NBIX has a market cap of 12.5B. Regarding current trading prices, TXMD is priced at $1.09, while NBIX trades at $126.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas NBIX's P/E ratio is 42.90. In terms of profitability, TXMD's ROE is -0.08%, compared to NBIX's ROE of +0.12%. Regarding short-term risk, TXMD is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs CTLT Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, TXMD is priced at $1.09, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas CTLT's P/E ratio is -27.84. In terms of profitability, TXMD's ROE is -0.08%, compared to CTLT's ROE of -0.11%. Regarding short-term risk, TXMD is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs VTRS Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, VTRS has a market cap of 10.4B. Regarding current trading prices, TXMD is priced at $1.09, while VTRS trades at $8.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas VTRS's P/E ratio is -2.79. In terms of profitability, TXMD's ROE is -0.08%, compared to VTRS's ROE of -0.21%. Regarding short-term risk, TXMD is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs ELAN Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, ELAN has a market cap of 6.7B. Regarding current trading prices, TXMD is priced at $1.09, while ELAN trades at $13.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas ELAN's P/E ratio is 17.97. In terms of profitability, TXMD's ROE is -0.08%, compared to ELAN's ROE of +0.06%. Regarding short-term risk, TXMD is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs LNTH Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, LNTH has a market cap of 5.5B. Regarding current trading prices, TXMD is priced at $1.09, while LNTH trades at $79.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas LNTH's P/E ratio is 22.56. In terms of profitability, TXMD's ROE is -0.08%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, TXMD is more volatile compared to LNTH. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs PRGO Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, PRGO has a market cap of 3.6B. Regarding current trading prices, TXMD is priced at $1.09, while PRGO trades at $26.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas PRGO's P/E ratio is -22.10. In terms of profitability, TXMD's ROE is -0.08%, compared to PRGO's ROE of -0.04%. Regarding short-term risk, TXMD is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs AMRX Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, AMRX has a market cap of 3.6B. Regarding current trading prices, TXMD is priced at $1.09, while AMRX trades at $7.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas AMRX's P/E ratio is -195.50. In terms of profitability, TXMD's ROE is -0.08%, compared to AMRX's ROE of -0.07%. Regarding short-term risk, TXMD is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs ALVOW Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, ALVOW has a market cap of 2.8B. Regarding current trading prices, TXMD is priced at $1.09, while ALVOW trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas ALVOW's P/E ratio is N/A. In terms of profitability, TXMD's ROE is -0.08%, compared to ALVOW's ROE of -0.23%. Regarding short-term risk, TXMD is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs ALVO Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, ALVO has a market cap of 2.8B. Regarding current trading prices, TXMD is priced at $1.09, while ALVO trades at $9.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas ALVO's P/E ratio is 25.27. In terms of profitability, TXMD's ROE is -0.08%, compared to ALVO's ROE of -0.23%. Regarding short-term risk, TXMD is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs HCM Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, HCM has a market cap of 2.7B. Regarding current trading prices, TXMD is priced at $1.09, while HCM trades at $14.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas HCM's P/E ratio is 74.20. In terms of profitability, TXMD's ROE is -0.08%, compared to HCM's ROE of +0.05%. Regarding short-term risk, TXMD is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs BGM Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, BGM has a market cap of 2.4B. Regarding current trading prices, TXMD is priced at $1.09, while BGM trades at $13.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas BGM's P/E ratio is -65.35. In terms of profitability, TXMD's ROE is -0.08%, compared to BGM's ROE of -0.03%. Regarding short-term risk, TXMD is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs BHC Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, TXMD is priced at $1.09, while BHC trades at $6.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas BHC's P/E ratio is -51.42. In terms of profitability, TXMD's ROE is -0.08%, compared to BHC's ROE of +0.05%. Regarding short-term risk, TXMD is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs DCPH Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, TXMD is priced at $1.09, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas DCPH's P/E ratio is -11.58. In terms of profitability, TXMD's ROE is -0.08%, compared to DCPH's ROE of -0.28%. Regarding short-term risk, TXMD is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs EMBCV Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, TXMD is priced at $1.09, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas EMBCV's P/E ratio is N/A. In terms of profitability, TXMD's ROE is -0.08%, compared to EMBCV's ROE of -0.07%. Regarding short-term risk, TXMD is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs SUPN Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, SUPN has a market cap of 1.8B. Regarding current trading prices, TXMD is priced at $1.09, while SUPN trades at $32.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas SUPN's P/E ratio is 29.08. In terms of profitability, TXMD's ROE is -0.08%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, TXMD is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs INDV Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, INDV has a market cap of 1.7B. Regarding current trading prices, TXMD is priced at $1.09, while INDV trades at $14.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas INDV's P/E ratio is -280.20. In terms of profitability, TXMD's ROE is -0.08%, compared to INDV's ROE of -0.01%. Regarding short-term risk, TXMD is more volatile compared to INDV. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs TARO Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, TXMD is priced at $1.09, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas TARO's P/E ratio is 30.05. In terms of profitability, TXMD's ROE is -0.08%, compared to TARO's ROE of +0.02%. Regarding short-term risk, TXMD is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs ANIP Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, ANIP has a market cap of 1.4B. Regarding current trading prices, TXMD is priced at $1.09, while ANIP trades at $65.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas ANIP's P/E ratio is -55.56. In terms of profitability, TXMD's ROE is -0.08%, compared to ANIP's ROE of -0.05%. Regarding short-term risk, TXMD is more volatile compared to ANIP. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs EVO Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, EVO has a market cap of 1.3B. Regarding current trading prices, TXMD is priced at $1.09, while EVO trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas EVO's P/E ratio is -5.61. In terms of profitability, TXMD's ROE is -0.08%, compared to EVO's ROE of -0.22%. Regarding short-term risk, TXMD is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs DVAX Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, DVAX has a market cap of 1.2B. Regarding current trading prices, TXMD is priced at $1.09, while DVAX trades at $9.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas DVAX's P/E ratio is -19.98. In terms of profitability, TXMD's ROE is -0.08%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, TXMD is less volatile compared to DVAX. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs AMPH Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, AMPH has a market cap of 1.2B. Regarding current trading prices, TXMD is priced at $1.09, while AMPH trades at $24.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas AMPH's P/E ratio is 8.90. In terms of profitability, TXMD's ROE is -0.08%, compared to AMPH's ROE of +0.19%. Regarding short-term risk, TXMD is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs HROW Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, HROW has a market cap of 1.1B. Regarding current trading prices, TXMD is priced at $1.09, while HROW trades at $30.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas HROW's P/E ratio is -50.26. In terms of profitability, TXMD's ROE is -0.08%, compared to HROW's ROE of -0.36%. Regarding short-term risk, TXMD is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs PCRX Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, PCRX has a market cap of 1.1B. Regarding current trading prices, TXMD is priced at $1.09, while PCRX trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas PCRX's P/E ratio is -10.82. In terms of profitability, TXMD's ROE is -0.08%, compared to PCRX's ROE of -0.13%. Regarding short-term risk, TXMD is more volatile compared to PCRX. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs PAHC Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, PAHC has a market cap of 967.9M. Regarding current trading prices, TXMD is priced at $1.09, while PAHC trades at $23.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas PAHC's P/E ratio is 30.62. In terms of profitability, TXMD's ROE is -0.08%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, TXMD is more volatile compared to PAHC. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs COLL Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, COLL has a market cap of 958.8M. Regarding current trading prices, TXMD is priced at $1.09, while COLL trades at $29.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas COLL's P/E ratio is 24.45. In terms of profitability, TXMD's ROE is -0.08%, compared to COLL's ROE of +0.19%. Regarding short-term risk, TXMD is more volatile compared to COLL. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs PETQ Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, TXMD is priced at $1.09, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas PETQ's P/E ratio is 83.73. In terms of profitability, TXMD's ROE is -0.08%, compared to PETQ's ROE of +0.05%. Regarding short-term risk, TXMD is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs AVDL Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, AVDL has a market cap of 888.1M. Regarding current trading prices, TXMD is priced at $1.09, while AVDL trades at $9.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas AVDL's P/E ratio is -35.31. In terms of profitability, TXMD's ROE is -0.08%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, TXMD is less volatile compared to AVDL. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs CRON Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, CRON has a market cap of 716.9M. Regarding current trading prices, TXMD is priced at $1.09, while CRON trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas CRON's P/E ratio is 13.29. In terms of profitability, TXMD's ROE is -0.08%, compared to CRON's ROE of +0.05%. Regarding short-term risk, TXMD is more volatile compared to CRON. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs EOLS Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, EOLS has a market cap of 598.3M. Regarding current trading prices, TXMD is priced at $1.09, while EOLS trades at $9.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas EOLS's P/E ratio is -10.43. In terms of profitability, TXMD's ROE is -0.08%, compared to EOLS's ROE of -9.32%. Regarding short-term risk, TXMD is more volatile compared to EOLS. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs BDSI Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, TXMD is priced at $1.09, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas BDSI's P/E ratio is 6.82. In terms of profitability, TXMD's ROE is -0.08%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, TXMD is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs EMBC Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, EMBC has a market cap of 571M. Regarding current trading prices, TXMD is priced at $1.09, while EMBC trades at $9.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas EMBC's P/E ratio is 10.98. In terms of profitability, TXMD's ROE is -0.08%, compared to EMBC's ROE of -0.07%. Regarding short-term risk, TXMD is more volatile compared to EMBC. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs ZYBT Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, ZYBT has a market cap of 440.7M. Regarding current trading prices, TXMD is priced at $1.09, while ZYBT trades at $9.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas ZYBT's P/E ratio is 155.00. In terms of profitability, TXMD's ROE is -0.08%, compared to ZYBT's ROE of +0.11%. Regarding short-term risk, TXMD is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs SIGA Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, SIGA has a market cap of 437.2M. Regarding current trading prices, TXMD is priced at $1.09, while SIGA trades at $6.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas SIGA's P/E ratio is 9.13. In terms of profitability, TXMD's ROE is -0.08%, compared to SIGA's ROE of +0.25%. Regarding short-term risk, TXMD is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs KMDA Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, KMDA has a market cap of 414M. Regarding current trading prices, TXMD is priced at $1.09, while KMDA trades at $7.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas KMDA's P/E ratio is 25.71. In terms of profitability, TXMD's ROE is -0.08%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, TXMD is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs ORGO Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, ORGO has a market cap of 409.7M. Regarding current trading prices, TXMD is priced at $1.09, while ORGO trades at $3.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas ORGO's P/E ratio is -20.19. In terms of profitability, TXMD's ROE is -0.08%, compared to ORGO's ROE of -0.06%. Regarding short-term risk, TXMD is more volatile compared to ORGO. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs TLRY Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, TLRY has a market cap of 369.2M. Regarding current trading prices, TXMD is priced at $1.09, while TLRY trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas TLRY's P/E ratio is -0.33. In terms of profitability, TXMD's ROE is -0.08%, compared to TLRY's ROE of -0.29%. Regarding short-term risk, TXMD is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs EBS Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, EBS has a market cap of 338.4M. Regarding current trading prices, TXMD is priced at $1.09, while EBS trades at $6.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas EBS's P/E ratio is -2.42. In terms of profitability, TXMD's ROE is -0.08%, compared to EBS's ROE of -0.27%. Regarding short-term risk, TXMD is more volatile compared to EBS. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs AQST Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, AQST has a market cap of 322.8M. Regarding current trading prices, TXMD is priced at $1.09, while AQST trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas AQST's P/E ratio is -5.60. In terms of profitability, TXMD's ROE is -0.08%, compared to AQST's ROE of +1.07%. Regarding short-term risk, TXMD is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs SNDL Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, SNDL has a market cap of 321.6M. Regarding current trading prices, TXMD is priced at $1.09, while SNDL trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas SNDL's P/E ratio is -4.17. In terms of profitability, TXMD's ROE is -0.08%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, TXMD is more volatile compared to SNDL. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs ALIM Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, TXMD is priced at $1.09, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas ALIM's P/E ratio is 5.28. In terms of profitability, TXMD's ROE is -0.08%, compared to ALIM's ROE of -0.32%. Regarding short-term risk, TXMD is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs TKNO Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, TKNO has a market cap of 297.1M. Regarding current trading prices, TXMD is priced at $1.09, while TKNO trades at $5.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas TKNO's P/E ratio is -12.09. In terms of profitability, TXMD's ROE is -0.08%, compared to TKNO's ROE of -0.28%. Regarding short-term risk, TXMD is more volatile compared to TKNO. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs LNDC Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, TXMD is priced at $1.09, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas LNDC's P/E ratio is -4.04. In terms of profitability, TXMD's ROE is -0.08%, compared to LNDC's ROE of +2.28%. Regarding short-term risk, TXMD is more volatile compared to LNDC. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs CGC Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, CGC has a market cap of 257.5M. Regarding current trading prices, TXMD is priced at $1.09, while CGC trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas CGC's P/E ratio is -0.30. In terms of profitability, TXMD's ROE is -0.08%, compared to CGC's ROE of -1.13%. Regarding short-term risk, TXMD is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs LFCR Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, LFCR has a market cap of 257M. Regarding current trading prices, TXMD is priced at $1.09, while LFCR trades at $6.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas LFCR's P/E ratio is -4.72. In terms of profitability, TXMD's ROE is -0.08%, compared to LFCR's ROE of -2.64%. Regarding short-term risk, TXMD is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs TYHT Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, TXMD is priced at $1.09, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas TYHT's P/E ratio is -1.61. In terms of profitability, TXMD's ROE is -0.08%, compared to TYHT's ROE of -1.41%. Regarding short-term risk, TXMD is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs ACB Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, ACB has a market cap of 223.9M. Regarding current trading prices, TXMD is priced at $1.09, while ACB trades at $4.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas ACB's P/E ratio is 18.55. In terms of profitability, TXMD's ROE is -0.08%, compared to ACB's ROE of +0.02%. Regarding short-term risk, TXMD is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs ESPR Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, ESPR has a market cap of 212.1M. Regarding current trading prices, TXMD is priced at $1.09, while ESPR trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas ESPR's P/E ratio is -1.26. In terms of profitability, TXMD's ROE is -0.08%, compared to ESPR's ROE of +0.40%. Regarding short-term risk, TXMD is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs REPH Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, TXMD is priced at $1.09, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas REPH's P/E ratio is -8.04. In terms of profitability, TXMD's ROE is -0.08%, compared to REPH's ROE of -0.22%. Regarding short-term risk, TXMD is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs OGI Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, OGI has a market cap of 171.4M. Regarding current trading prices, TXMD is priced at $1.09, while OGI trades at $1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas OGI's P/E ratio is 9.85. In terms of profitability, TXMD's ROE is -0.08%, compared to OGI's ROE of +0.05%. Regarding short-term risk, TXMD is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs BIOA Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, BIOA has a market cap of 155.6M. Regarding current trading prices, TXMD is priced at $1.09, while BIOA trades at $4.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas BIOA's P/E ratio is -2.19. In terms of profitability, TXMD's ROE is -0.08%, compared to BIOA's ROE of -0.38%. Regarding short-term risk, TXMD is less volatile compared to BIOA. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs DERM Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, DERM has a market cap of 151.7M. Regarding current trading prices, TXMD is priced at $1.09, while DERM trades at $6.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas DERM's P/E ratio is -17.59. In terms of profitability, TXMD's ROE is -0.08%, compared to DERM's ROE of -0.52%. Regarding short-term risk, TXMD is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs THTX Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, THTX has a market cap of 116.3M. Regarding current trading prices, TXMD is priced at $1.09, while THTX trades at $2.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas THTX's P/E ratio is -36.14. In terms of profitability, TXMD's ROE is -0.08%, compared to THTX's ROE of +0.16%. Regarding short-term risk, TXMD is less volatile compared to THTX. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs SCTL Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, TXMD is priced at $1.09, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas SCTL's P/E ratio is -7.86. In terms of profitability, TXMD's ROE is -0.08%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, TXMD is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs PROC Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, PROC has a market cap of 114M. Regarding current trading prices, TXMD is priced at $1.09, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas PROC's P/E ratio is 1.53. In terms of profitability, TXMD's ROE is -0.08%, compared to PROC's ROE of -2.22%. Regarding short-term risk, TXMD is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs IRWD Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, IRWD has a market cap of 113.5M. Regarding current trading prices, TXMD is priced at $1.09, while IRWD trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas IRWD's P/E ratio is -3.69. In terms of profitability, TXMD's ROE is -0.08%, compared to IRWD's ROE of +0.10%. Regarding short-term risk, TXMD is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs CRDL Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, CRDL has a market cap of 102.5M. Regarding current trading prices, TXMD is priced at $1.09, while CRDL trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas CRDL's P/E ratio is -3.54. In terms of profitability, TXMD's ROE is -0.08%, compared to CRDL's ROE of -2.08%. Regarding short-term risk, TXMD is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs QNTM Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, QNTM has a market cap of 101.8M. Regarding current trading prices, TXMD is priced at $1.09, while QNTM trades at $35.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas QNTM's P/E ratio is -2.65. In terms of profitability, TXMD's ROE is -0.08%, compared to QNTM's ROE of -1.88%. Regarding short-term risk, TXMD is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs OPTN Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, TXMD is priced at $1.09, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas OPTN's P/E ratio is -4.42. In terms of profitability, TXMD's ROE is -0.08%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, TXMD is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs ZOM Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, TXMD is priced at $1.09, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas ZOM's P/E ratio is -1.62. In terms of profitability, TXMD's ROE is -0.08%, compared to ZOM's ROE of -0.55%. Regarding short-term risk, TXMD is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs GRVI Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, TXMD is priced at $1.09, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas GRVI's P/E ratio is 26.05. In terms of profitability, TXMD's ROE is -0.08%, compared to GRVI's ROE of -5.25%. Regarding short-term risk, TXMD is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs INCR Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, INCR has a market cap of 71.7M. Regarding current trading prices, TXMD is priced at $1.09, while INCR trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas INCR's P/E ratio is -3.62. In terms of profitability, TXMD's ROE is -0.08%, compared to INCR's ROE of -0.07%. Regarding short-term risk, TXMD is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs ZYNE Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, TXMD is priced at $1.09, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, TXMD's ROE is -0.08%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, TXMD is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs SSIC Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, TXMD is priced at $1.09, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas SSIC's P/E ratio is 11.93. In terms of profitability, TXMD's ROE is -0.08%, compared to SSIC's ROE of +0.03%. Regarding short-term risk, TXMD is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs CPIX Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, CPIX has a market cap of 65.1M. Regarding current trading prices, TXMD is priced at $1.09, while CPIX trades at $4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas CPIX's P/E ratio is -18.12. In terms of profitability, TXMD's ROE is -0.08%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, TXMD is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs VLNS Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, TXMD is priced at $1.09, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas VLNS's P/E ratio is -1.03. In terms of profitability, TXMD's ROE is -0.08%, compared to VLNS's ROE of N/A. Regarding short-term risk, TXMD is more volatile compared to VLNS. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs ASRT Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, ASRT has a market cap of 60.3M. Regarding current trading prices, TXMD is priced at $1.09, while ASRT trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas ASRT's P/E ratio is -1.97. In terms of profitability, TXMD's ROE is -0.08%, compared to ASRT's ROE of -0.24%. Regarding short-term risk, TXMD is less volatile compared to ASRT. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs JUPW Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, TXMD is priced at $1.09, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas JUPW's P/E ratio is -2.41. In terms of profitability, TXMD's ROE is -0.08%, compared to JUPW's ROE of -9.40%. Regarding short-term risk, TXMD is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs SXTC Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, SXTC has a market cap of 47.9M. Regarding current trading prices, TXMD is priced at $1.09, while SXTC trades at $1.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas SXTC's P/E ratio is 0.01. In terms of profitability, TXMD's ROE is -0.08%, compared to SXTC's ROE of +0.47%. Regarding short-term risk, TXMD is more volatile compared to SXTC. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs QLI Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, TXMD is priced at $1.09, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas QLI's P/E ratio is -4.92. In terms of profitability, TXMD's ROE is -0.08%, compared to QLI's ROE of -0.16%. Regarding short-term risk, TXMD is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs HEXO Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, TXMD is priced at $1.09, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas HEXO's P/E ratio is -0.26. In terms of profitability, TXMD's ROE is -0.08%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, TXMD is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs EGRX Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, EGRX has a market cap of 30.5M. Regarding current trading prices, TXMD is priced at $1.09, while EGRX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas EGRX's P/E ratio is 2.70. In terms of profitability, TXMD's ROE is -0.08%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, TXMD is more volatile compared to EGRX. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs RMTI Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, RMTI has a market cap of 30.4M. Regarding current trading prices, TXMD is priced at $1.09, while RMTI trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas RMTI's P/E ratio is -89.00. In terms of profitability, TXMD's ROE is -0.08%, compared to RMTI's ROE of -0.01%. Regarding short-term risk, TXMD is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs SCYX Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, SCYX has a market cap of 28.6M. Regarding current trading prices, TXMD is priced at $1.09, while SCYX trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas SCYX's P/E ratio is -1.31. In terms of profitability, TXMD's ROE is -0.08%, compared to SCYX's ROE of -0.48%. Regarding short-term risk, TXMD is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs KALA Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, KALA has a market cap of 26.1M. Regarding current trading prices, TXMD is priced at $1.09, while KALA trades at $4.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas KALA's P/E ratio is -0.55. In terms of profitability, TXMD's ROE is -0.08%, compared to KALA's ROE of -3.69%. Regarding short-term risk, TXMD is more volatile compared to KALA. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs CYTH Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, TXMD is priced at $1.09, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas CYTH's P/E ratio is -0.80. In terms of profitability, TXMD's ROE is -0.08%, compared to CYTH's ROE of +7.50%. Regarding short-term risk, TXMD is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs DRRX Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, DRRX has a market cap of 21.5M. Regarding current trading prices, TXMD is priced at $1.09, while DRRX trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas DRRX's P/E ratio is -1.44. In terms of profitability, TXMD's ROE is -0.08%, compared to DRRX's ROE of -0.93%. Regarding short-term risk, TXMD is less volatile compared to DRRX. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs IXHL Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, IXHL has a market cap of 20.5M. Regarding current trading prices, TXMD is priced at $1.09, while IXHL trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas IXHL's P/E ratio is -0.18. In terms of profitability, TXMD's ROE is -0.08%, compared to IXHL's ROE of -2.03%. Regarding short-term risk, TXMD is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs GELS Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, GELS has a market cap of 15.1M. Regarding current trading prices, TXMD is priced at $1.09, while GELS trades at $1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas GELS's P/E ratio is -6.67. In terms of profitability, TXMD's ROE is -0.08%, compared to GELS's ROE of -0.21%. Regarding short-term risk, TXMD is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs FLGC Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, FLGC has a market cap of 15.1M. Regarding current trading prices, TXMD is priced at $1.09, while FLGC trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas FLGC's P/E ratio is -0.73. In terms of profitability, TXMD's ROE is -0.08%, compared to FLGC's ROE of -2.55%. Regarding short-term risk, TXMD is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs ACRX Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, TXMD is priced at $1.09, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas ACRX's P/E ratio is -0.31. In terms of profitability, TXMD's ROE is -0.08%, compared to ACRX's ROE of -2.49%. Regarding short-term risk, TXMD is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs PRPH Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, PRPH has a market cap of 14M. Regarding current trading prices, TXMD is priced at $1.09, while PRPH trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas PRPH's P/E ratio is -0.14. In terms of profitability, TXMD's ROE is -0.08%, compared to PRPH's ROE of -1.59%. Regarding short-term risk, TXMD is less volatile compared to PRPH. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs COSM Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, COSM has a market cap of 12.6M. Regarding current trading prices, TXMD is priced at $1.09, while COSM trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas COSM's P/E ratio is -0.40. In terms of profitability, TXMD's ROE is -0.08%, compared to COSM's ROE of -0.51%. Regarding short-term risk, TXMD is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs AYTU Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, AYTU has a market cap of 12.3M. Regarding current trading prices, TXMD is priced at $1.09, while AYTU trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas AYTU's P/E ratio is -1.34. In terms of profitability, TXMD's ROE is -0.08%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, TXMD is more volatile compared to AYTU. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.
TXMD vs AGRX Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, TXMD is priced at $1.09, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas AGRX's P/E ratio is -0.89. In terms of profitability, TXMD's ROE is -0.08%, compared to AGRX's ROE of +0.93%. Regarding short-term risk, TXMD is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs TLPH Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, TLPH has a market cap of 9.3M. Regarding current trading prices, TXMD is priced at $1.09, while TLPH trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas TLPH's P/E ratio is -1.04. In terms of profitability, TXMD's ROE is -0.08%, compared to TLPH's ROE of -1.29%. Regarding short-term risk, TXMD is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs IMCC Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, IMCC has a market cap of 8.5M. Regarding current trading prices, TXMD is priced at $1.09, while IMCC trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas IMCC's P/E ratio is -1.99. In terms of profitability, TXMD's ROE is -0.08%, compared to IMCC's ROE of -1.52%. Regarding short-term risk, TXMD is less volatile compared to IMCC. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs NLTX Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, TXMD is priced at $1.09, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas NLTX's P/E ratio is -0.28. In terms of profitability, TXMD's ROE is -0.08%, compared to NLTX's ROE of -0.49%. Regarding short-term risk, TXMD is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs YCBD Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, YCBD has a market cap of 7.7M. Regarding current trading prices, TXMD is priced at $1.09, while YCBD trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas YCBD's P/E ratio is 0.01. In terms of profitability, TXMD's ROE is -0.08%, compared to YCBD's ROE of -0.01%. Regarding short-term risk, TXMD is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs LCI Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, TXMD is priced at $1.09, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas LCI's P/E ratio is -0.04. In terms of profitability, TXMD's ROE is -0.08%, compared to LCI's ROE of +1.66%. Regarding short-term risk, TXMD is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs BGXX Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, TXMD is priced at $1.09, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas BGXX's P/E ratio is -0.76. In terms of profitability, TXMD's ROE is -0.08%, compared to BGXX's ROE of -0.88%. Regarding short-term risk, TXMD is less volatile compared to BGXX. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs ADMP Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, TXMD is priced at $1.09, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas ADMP's P/E ratio is -0.08. In terms of profitability, TXMD's ROE is -0.08%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, TXMD is less volatile compared to ADMP. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.
TXMD vs SISI Comparison
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 12.6M. In comparison, SISI has a market cap of 6.6M. Regarding current trading prices, TXMD is priced at $1.09, while SISI trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of -5.74, whereas SISI's P/E ratio is N/A. In terms of profitability, TXMD's ROE is -0.08%, compared to SISI's ROE of -1.41%. Regarding short-term risk, TXMD is less volatile compared to SISI. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.